Lifeward secures $20M days after closing NY medtech acquisition

The mobility device manufacturer raised capital shortly after acquiring Oratech Pharmaceuticals.

Apr. 3, 2026 at 7:18pm

Got story updates? Submit your updates here. ›

A highly reflective, geometric medical device or pharmaceutical product made of polished metal and glass, floating on a plain white background and dramatically lit to create deep shadows, symbolizing the advanced technology and innovation behind Lifeward's latest acquisition and capital raise.Lifeward's strategic investments in medical technology signal the company's ambitions to expand beyond mobility devices.Worcester Today

Days after Lifeward completed an approximately $47-million acquisition of Oratech Pharmaceuticals, a subsidiary of Oramed Pharmaceuticals, the Marlborough-based mobility device manufacturer secured $20 million in capital funding through a combination of equity and debt securities issued to two unidentified investors.

Why it matters

The acquisition and capital raise come as Lifeward, formerly known as ReWalk Robotics, works to regain compliance with Nasdaq listing requirements after struggling with its stock price falling below the $1 per share minimum. The additional funding will help support Lifeward's continued development and commercialization of mobility devices for individuals with lower-limb disabilities.

The details

Lifeward issued a combination of securities to two unidentified investors, including equity and debt, according to a Thursday filing with the U.S. Securities and Exchange Commission. The acquisition of Oratech Pharmaceuticals, which develops medical technology to protect proteins in medications and increase their absorption into the body, closed on March 25. As part of the acquisition, Lifeward issued 2.26 million shares, 1.3 million warrants, and $10 million in convertible notes to Oramed.

  • Lifeward completed its acquisition of Oratech Pharmaceuticals on March 25, 2026.
  • Lifeward regained compliance with Nasdaq listing requirements on March 11, 2026, seven months after first receiving a warning it was at risk of being delisted.
  • In August 2025, Lifeward received notice that its stock price had fallen below the $1 per share minimum for 30 consecutive business days.

The players

Lifeward

A Marlborough-based manufacturer of mobility devices for individuals with lower-limb disabilities, such as exoskeletons, anti-gravity treadmills, and cycling machines. Formerly known as ReWalk Robotics, the company was founded in 2001.

Oratech Pharmaceuticals

A subsidiary of New York-based Oramed Pharmaceuticals that develops medical technology to protect proteins in medications and increase their absorption into the body.

Oramed Pharmaceuticals

A New York-based pharmaceutical company that owns Oratech Pharmaceuticals.

Got photos? Submit your photos here. ›

What’s next

Lifeward will use the $20 million in capital funding to support the continued development and commercialization of its mobility devices for individuals with lower-limb disabilities, as the company works to maintain its Nasdaq listing compliance.

The takeaway

The acquisition of Oratech Pharmaceuticals and the subsequent $20 million capital raise demonstrate Lifeward's strategic efforts to strengthen its product portfolio and financial position as it navigates the challenges of maintaining its public company status. The additional funding will help the company advance its mission of providing innovative mobility solutions for those with lower-limb disabilities.